Dachaigh › Cancer Ovarian › Michigan › Detroit
Sgrùdaidhean clionaigeach Cancer Ovarian ann an Detroit, MI
Tha 26 sgrùdaidhean airson Cancer Ovarian a’ lorg phàirtichean aig làraichean ann agus timcheall air Detroit (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
The Vanguard Study: Testing a New Way to Screen for Cancer
A’ fastadhFàilte do shaor-thoilich fhallain
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
A’ fastadhÌre 2/3
- Henry Ford Hospital, Detroit
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
A’ fastadhÌre 1/2
- Research Site, Detroit
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
A’ fastadhSgrùdadh amharc
- Henry Ford Health, Detroit
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
A’ fastadhÌre 1/2
- Karmanos Cancer Institute, Detroit
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A’ fastadhÌre 2
- Site 0101 - Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
A’ fastadhÌre 1/2
- Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
A’ fastadhÌre 3
- Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
A’ fastadhÌre 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
A’ fastadhÌre 2
- Karmanos Cancer Institute - Detroit /ID# 277085, Detroit
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A’ fastadhÌre 3
- Henry Ford Cancer - Detroit, Detroit
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
A’ fastadhÌre 2
- Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A’ fastadhÌre 1
- Karmanos Cancer Institiute, Detroit
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
A’ fastadhÌre 3
- Karmanos Cancer Institute, Detroit
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
A’ fastadhÌre 1
- Karmanos Cancer Institute, Detroit
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
A’ fastadhÌre 1
- Karmanos Cancer Center, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
A’ fastadhÌre 3
- Henry Ford Health Saint John Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- Karmanos Cancer Institute, Detroit
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
A’ fastadhÌre 1
- Karmanos Cancer Institute, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A’ fastadhÌre 1/2
- Henry Ford Health Hospital, Detroit
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
A’ fastadhÌre 2
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
A’ fastadhÌre 2
- Karmanos Cancer Institute - Detroit /ID# 272112, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
A’ fastadhÌre 1/2
- Karmanos Cancer Institute, Detroit
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
A’ fastadhÌre 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
A’ fastadhÌre 1/2
- Karmanos Cancer Institute, Detroit
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
A’ fastadhÌre 1
- Karmanos Cancer Institute, Detroit
Sgrùdaidhean Cancer Ovarian ann am bailtean eile
- Houston, TX89 sgrùdaidhean
- New York City, NY69 sgrùdaidhean
- Boston, MA61 sgrùdaidhean
- Los Angeles, CA50 sgrùdaidhean
- Nashville, TN49 sgrùdaidhean
- Arlington, VA46 sgrùdaidhean
- Philadelphia, PA44 sgrùdaidhean
- Columbus, OH39 sgrùdaidhean
- St. Louis, MO38 sgrùdaidhean
- Chicago, IL36 sgrùdaidhean
- San Antonio, TX31 sgrùdaidhean
- Cleveland, OH30 sgrùdaidhean
Sgrùdaidhean eile ann an Detroit
- Aillse Sgamhain Neo-chealla-beag44 sgrùdaidhean
- Aillse a' bhroilleach33 sgrùdaidhean
- Aillse (gach seòrsa)29 sgrùdaidhean
- Aillse colorectal26 sgrùdaidhean
- Ailse metastatach24 sgrùdaidhean
- Aillse Prostata22 sgrùdaidhean
- Ailse Endometrial21 sgrùdaidhean
- Ailseachadh nan Sgamhan20 sgrùdaidhean
- Myeloma iomaill19 sgrùdaidhean
- Aillse a' Bhroinn16 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil15 sgrùdaidhean
- Leukemia myeloid geur14 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.